According to Ionis Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of 16.0.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 18.8 | 100.43% |
2022-12-31 | 9.37 | 68.2% |
2021-12-31 | 5.57 | -47.65% |
2020-12-31 | 10.6 | 111.34% |
2019-12-31 | 5.03 | -19.87% |
2018-12-31 | 6.28 | -63.45% |
2017-12-31 | 17.2 | -70.49% |
2016-12-31 | 58.2 | 56.85% |
2015-12-31 | 37.1 | 30.85% |
2014-12-31 | 28.4 | 131.33% |
2013-12-31 | 12.3 | 111.55% |
2012-12-31 | 5.80 | 38.21% |
2011-12-31 | 4.19 | 1.97% |
2010-12-31 | 4.11 | 13.13% |
2009-12-31 | 3.64 | -72.44% |
2008-12-31 | 13.2 | -90.16% |
2007-12-31 | 134 | 1335.29% |
2006-12-31 | 9.35 | -93.42% |
2005-12-31 | 142 | -3121.29% |
2004-12-31 | -4.70 | -187.41% |
2003-12-31 | 5.38 | 129.69% |
2002-12-31 | 2.34 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | -6.34 | -139.65% | Bahamas |
NRC Health
NRC | 16.7 | 4.44% | ๐บ๐ธ USA |